Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition for detecting tumor residues of mother cell plasma cell-like dendritic cells and application of composition for detecting tumor residues of mother cell plasma cell-like dendritic cells

A composition and plasma cell technology, which can be used in measurement devices, biological tests, material inspection products, etc., can solve the problems of lack of detection methods and methods for the micro-residue of blastic plasmacytoid dendritic cell tumors, etc., and achieve a guaranteed accuracy rate. , Reduce missed detection and false detection, avoid the effect of missed detection or false detection

Pending Publication Date: 2022-04-15
武汉康圣达医学检验所有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently a lack of means and methods for the detection of minimal residual blastic plasmacytoid dendritic cell tumors in patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for detecting tumor residues of mother cell plasma cell-like dendritic cells and application of composition for detecting tumor residues of mother cell plasma cell-like dendritic cells
  • Composition for detecting tumor residues of mother cell plasma cell-like dendritic cells and application of composition for detecting tumor residues of mother cell plasma cell-like dendritic cells
  • Composition for detecting tumor residues of mother cell plasma cell-like dendritic cells and application of composition for detecting tumor residues of mother cell plasma cell-like dendritic cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] This embodiment provides a kit for detecting residual tumor of blastic plasmacytoid dendritic cells, including HLA-DRAPC-cy7, CD4 APC, CD11b PE-cy7, CD15 BV450, CD56 FITC, CD64 FITC, CD123 PE, CD303BV421 , CD304 PE-cy7, CD34 PerCP, CD33APC and CD45 V500 antibodies, erythrocyte lysate, PBS buffer, wherein, composition one includes CD56 FITC, CD123 PE, CD34 PerCP, CD4 APC, CD304 PE-cy7, HLA-DRAPC- cy7, CD303 BV421 and CD45 V500 antibodies, composition 2 includes CD64 FITC, CD123 PE, CD33 APC, CD11b PE-cy7, HLA-DRAPC-cy7, CD15 BV450 and CD45 V500 antibodies.

[0049] Red blood cell lysate was purchased from BD Company, including the following components: ammonium chloride, potassium dihydrogen phosphate, disodium edetate and paraformaldehyde;

[0050] The concentration of PBS buffer (phosphate buffer) is 0.01M, the pH is 7.2-7.4, including the following components: potassium dihydrogen phosphate 1.8mmol / L, disodium hydrogen phosphate 10mmol / L, sodium chloride 137mmol / L and...

Embodiment 2

[0053] The difference between this example and Example 1 is that in composition one, the mass ratio of CD56 FITC, CD123 PE, CD34 PerCP, CD4 APC, CD304 PE-cy7, HLA-DR APC-cy7, CD303 BV421 and CD45 V500 antibodies is 12:24:100:3.6:60:30:30:80, the rest of the conditions are consistent with Example 1.

experiment example 1

[0059] The kit in Example 1 was used to detect and analyze the samples of patients with blastic plasmacytoid dendritic cell tumor and the samples of normal test subjects, and the detection steps were as follows:

[0060] S1. Add 23 μL of Composition 1 and 18 μL of Composition 2 into two different test tubes, and then add 200 μL of the sample to be tested in both test tubes (adjust the cell solubility to 10 7 / mL), incubate in the dark for 15min;

[0061] S2. Add 1 mL of erythrocyte lysate to each of the two test tubes, mix evenly, and then stand in the dark for 8 minutes at room temperature to obtain a lysate mixture;

[0062] S3. Centrifuge the lysis mixture at 300 rct / min for 5 minutes, remove the supernatant, and obtain a lysis precipitate;

[0063] Step S4, add 1mL PBS to the lysed precipitate and mix evenly, then centrifuge at 150rct / min for 5min, then add 150μL PBS to resuspend to obtain a resuspension solution;

[0064] S5, detect the resuspended solution on the flow ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a mother cell plasma cell-like dendritic cell tumor residue detection composition and a mother cell plasma cell-like dendritic cell tumor residue detection composition, the mother cell plasma cell-like dendritic cell tumor residue detection composition comprises a first composition and a second composition, the first composition at least comprises a CD56 antibody, a CD123 antibody, a CD34 antibody, a CD4 antibody, a CD304 antibody, an HLA-DR antibody, a CD303 antibody and a CD45 antibody, and the second composition at least comprises a first antibody and a second antibody. The composition II at least comprises a CD64 antibody, a CD123 antibody, a CD33 antibody, a CD11b antibody, an HLA-DR antibody, a CD15 antibody and a CD45 antibody. The composition provided by the invention not only can distinguish abnormal tumor cells from normal cells, but also can distinguish dendritic cells from myeloid cells, is high in detection accuracy, and can effectively avoid diagnosis errors caused by missing detection or false detection.

Description

technical field [0001] The invention relates to the field of biological detection, in particular to a composition for detecting residual tumor of blastic plasmacytoid dendritic cells and an application thereof. Background technique [0002] Blastocytic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy derived from immature plasmacytoid dendritic cells and is often aggressive clinically. The histopathology of BPDCN lesions mostly showed pleomorphic cells, tumor cells were single, diffusely distributed, chromatin was usually dispersed, agranular, irregular nuclear membrane, prominent nucleoli, and enhanced mitosis. There was no vascular invasion and coagulation necrosis. It often involves the dermis, may invade the subcutaneous fat tissue, and may also cause damage to the skin appendages, but generally does not involve the epidermis. [0003] BPDCN usually expresses CD4, CD56, CD43, CD45RA and at least one pDCs-related antigen, such as CD123, TCL-1, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/58G01N15/14
Inventor 马耀坤杜雯郑金娥刘钰覃磊商芳影岳佩琼宋亮亮黄士昂
Owner 武汉康圣达医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com